Legislators
Bills
Statements
Lobbying
Travel
Searching...- Lobbying
- Lobbying by Sun Pharma (formerly Ranbaxy Inc.)
Lobbying Relationship
Bills mentioned
S.214: Preserve Access to Affordable Generics Act
Sponsor: Amy Klobuchar (D-Minn.)
S.27: Hill Creek Cultural Preservation and Energy Development Act
Sponsor: Orrin G. Hatch (R-Utah)
H.R.1483: Stop Outsourcing Banking Enforcement and Examination Act
Sponsor: Maxine Waters (D-Calif.)
S.959: Pharmaceutical Quality, Security, and Accountability Act
Sponsor: Tom Harkin (D-Iowa)
S.957: Drug Supply Chain Security Act
Sponsor: Michael Bennet (D-Colo.)
H.R.1919: Safeguarding America's Pharmaceuticals Act of 2013
Sponsor: Robert E. Latta (R-Ohio)
H.R.2186: VALID Compounding Act
Sponsor: Edward J. Markey (D-Mass.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
| Lobbyist | Covered positions? |
|---|---|
| Todd Tuten | Rep Michael Bilirakis; 91-92, 93-95, 98-01 |
| John Jonas | n/a |
| Caitlin McCormick | n/a |
| Anurag Varma | n/a |
| Kendall Hussey | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate